OpenEvidence revenue and valuation
Specter estimates OpenEvidence's annual revenue at $240M to $390M and its valuation at $12.5B to $18B. The company last reported $150M revenue in December 2025 and was priced at $15B in September 2026.
- Estimated revenue
- $240M–$390M
- Estimated valuation
- $12.5B–$18B
- Reported revenue
- $150M
- Total funding
- $1.03B
- Founded
- 2021
- Headquarters
- Miami, United States
- Employees
- 146
OpenEvidence revenue
OpenEvidence last reported $150M revenue in December 2025. Specter's model puts current revenue between $240M and $390M, anchored to two reported figures.
Monthly data
| Month | Specter estimate | Low | High | Reported figure |
|---|---|---|---|---|
| $300M | $240M | $390M | ||
| $300M | $240M | $380M | ||
| $290M | $240M | $350M | ||
| $300M | $250M | $360M | ||
| $270M | $210M | $350M | ||
| $250M | $193M | $310M | ||
| $220M | $177M | $280M | ||
| $200M | $160M | $250M | ||
| $183M | $147M | $230M | ||
| $166M | $135M | $200M | ||
| $150M | $125M | $180M | $150M | |
| $87M | $71M | $106M | ||
| $50M | $42M | $60M | $50M | |
| $24M | $17M | $31M | ||
| $20M | $13M | $27M | ||
| $17M | $12M | $23M | ||
| $12M | $7.2M | $16M | ||
| $13M | $7.4M | $19M | ||
| $11M | $7.3M | $14M | ||
| $11M | $7M | $14M | ||
| $11M | $6.7M | $14M | ||
| $6.6M | $3.3M | $9.9M | ||
| $4.7M | $3.1M | $6.3M | ||
| $5.1M | $3.7M | $6.5M | ||
| $4.3M | $2.5M | $6.1M | ||
| $2.8M | $1.9M | $3.7M | ||
| $3.7M | $1.4M | $6.1M | ||
| $2.2M | $1.1M | $3.4M | ||
| $2.2M | $1M | $3.3M |
| Date | Reported figure | Source |
|---|---|---|
| $150M revenue | ||
| $50M ARR |
OpenEvidence valuation
OpenEvidence's valuation rose from $425M at its Seed in July 2022 to $15B at its Series E in September 2026. Specter's live estimate sits between $12.5B and $18B.
Monthly data
| Month | Specter estimate | Low | High | Reported valuation |
|---|---|---|---|---|
| $15B | $12.5B | $18B | $15B (press) | |
| $15B | $12.5B | $18B | $15B (round) | |
| $14.4B | $10.6B | $19.8B | ||
| $13.9B | $10.3B | $18.9B | ||
| $13.4B | $10.2B | $17.7B | ||
| $12.9B | $10.1B | $16.6B | ||
| $12.4B | $10B | $15.4B | ||
| $12B | $9.98B | $14.4B | $12B (press) | |
| $12B | $9.83B | $14.6B | ||
| $12B | $9.98B | $14.4B | $12B (round) | |
| $12B | $9.98B | $14.4B | $12B (press) | |
| $3B | $2.5B | $3.61B | $3B (press) | |
| $6B | $4.99B | $7.21B | $6B (round) | |
| $3.5B | $2.91B | $4.21B | $3.5B (press) | |
| $3.5B | $2.91B | $4.21B | $3.5B (press) | |
| $3.5B | $2.91B | $4.21B | $3.5B (round) | |
| $2.72B | $1.99B | $3.73B | ||
| $2.12B | $1.6B | $2.82B | ||
| $1.65B | $1.29B | $2.11B | ||
| $1.28B | $1.04B | $1.59B | ||
| $1B | $830M | $1.2B | $1B (round) | |
| $970M | $450M | $2.1B | ||
| $950M | $490M | $1.83B | ||
| $920M | $460M | $1.85B | ||
| $900M | $480M | $1.67B | ||
| $870M | $460M | $1.65B | ||
| $850M | $470M | $1.54B | ||
| $820M | $520M | $1.3B | ||
| $800M | $510M | $1.27B |
OpenEvidence funding rounds
| Date | Round | Raised | Post-money valuation | Lead investors |
|---|---|---|---|---|
| Series E | $250M | $15B | Byers Capital, Andreessen Horowitz | |
| Secondary | Undisclosed | Undisclosed | Undisclosed | |
| Series D | $250M | $12B | DST Global, Thrive Capital | |
| Series C | $200M | $6B | Google Ventures | |
| Secondary | $15.6M | Undisclosed | Undisclosed | |
| Series B | $210M | $3.5B | Kleiner Perkins, Google Ventures | |
| Series A | $75M | $1B | Sequoia Capital | |
| Seed | $27M | $425M | Undisclosed | |
| Seed | $5M | Undisclosed | Daniel Nadler |
OpenEvidence competitors
The medical intelligence market is shifting from static repositories to conversational AI synthesis.
| Company | Revenue | Valuation |
|---|---|---|
| $240M–$390M | $12.5B–$18B | |
| $47M–$230M | No estimate | |
| $600K–$1.3M | $2.2B–$13B | |
| $3.1M–$9.4M | $4.6M–$28M | |
| $3.9M–$15M | $195M–$230M |
OpenEvidence revenue and valuation FAQ
What is OpenEvidence's revenue?
Specter estimates OpenEvidence's annual revenue at $240M to $390M as of October 2026. OpenEvidence last reported $150M revenue in December 2025.
What is OpenEvidence's valuation?
OpenEvidence's latest post-money valuation is $15B, from a September 2026 Series E. Specter's live estimate is $12.5B to $18B.
What is OpenEvidence's revenue multiple?
OpenEvidence is valued at about 100× revenue, based on its $15B September 2026 valuation and $150M last reported revenue. That works out to roughly $1.03M of revenue per employee.
How much funding has OpenEvidence raised?
$1.03B across nine rounds, from a $5M Seed in November 2021 to a $250M Series E in September 2026.
Who invested in OpenEvidence?
31 investors, including Andreessen Horowitz, Byers Capital, DST Global, Google Ventures, Kleiner Perkins and Thrive Capital.
Who are OpenEvidence's competitors?
UpToDate, ClinicalKey Now, PulseLife and Vera Health. Specter ranks 29 competitors for OpenEvidence.